https://www.biopharmadive.com/news/kelun-merck-adc-trop2-first-line-treatment-lung-cancer/806409/
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential approval in the first-line setting.
first line treatmentkelunmercktoutadc